S'abonner

Bixa orellana ethyl acetate fraction and its isolated compound ellagic acid attenuate the progression of MIA-induced osteoarthritis in rat knees - 11/11/23

Doi : 10.1016/j.biopha.2023.115644 
Luis Ângelo Macêdo Santiago a, , 1 , Ana Caroline Santos Ataíde b, Danilo de Araújo Morais c, Aldilene da Silva Lima d, Nathálya dos Santos Martins e, Adriana Vivian Costa Araújo Dourado f, Rachel Melo Ribeiro b, Lídio Gonçalves Lima-Neto a, c, Joicy Cortez de Sá Sousa c, Cláudia Quintino da Rocha d, Maria do Socorro de Sousa Cartágenes b, Rafael Cardoso Carvalho b, Eduardo Martins de Sousa a, b, c
a Graduate Program in Biodiversity and Biotechnology of the Bionorte Network, - BIONORTE - Federal University of Maranhão, Maranhão-UFMA, São Luis 65080-805, Brazil 
b Graduate Program in Health Sciences - Federal University of Maranhão-UFMA, São Luis 65080-805, Brazil 
c Graduate Program in Microbial Biology, CEUMA University—UniCEUMA, São Luís 65075-120, Brazil 
d Graduate Program in Chemistry, Federal University of Maranhão-UFMA, São Luis 65080-805, Brazil 
e Chapadinha Science Center, Federal University of Maranhão-UFMA, Chapadinha 65500-00, Brazil 
f Diagnosi Veterinary Image, São Luis 65071-640, Brazil 

Correspondence to: Graduate Program in Biodiversity and Biotechnology of the Bionorte Network, - BIONORTE, Maranhão - Federal University of Maranhão - UFMA, São Luis, Maranhão 65080-805, Brazil.Graduate Program in Biodiversity and Biotechnology of the Bionorte Network, - BIONORTE, Maranhão - Federal University of Maranhão - UFMASão LuisMaranhão65080-805Brazil

Abstract

Osteoarthritis (OA) is a pathology that is characterized by progressive erosion of articular cartilage. In this context, medicinal plants have become relevant tools regarding their potential role in the prevention and treatment of OA, being safe and effective. The aim of this work was investigate the therapeutic efficacy of the ethyl acetate fraction of Bixa orellana leaves (BoEA) and ellagic acid (ElAc) for the therapeutic treatment of OA induced by monosodium iodoacetate (MIA) in rats. The plant material was extracted via maceration with 70 % hydroalcoholic solvent (BoHE). The ethyl acetate (BoEA) fraction was by solvents in increasing order of polarity. The ElAc was identified and isolated in BoEA using high performance liquid chromatography (HPLC-DAD) and analytical curve. The OA was induced using MIA in the right knee at the knee joint. Doses of BoEA and ElAc were administered daily (every 24 h, orally) at concentrations of 50, 100 and 50 mg/kg, respectively, for 28 days after induced OA. We evaluated the animals through clinical and radiological examinations every 7 days and, on the 29th day, the animals were euthanized, the joints being removed for histopathological analysis and the serum for cytokine analysis. BoEA and ElAc compounds reduced inflammation and nociception in OA and were as effective as indomethacin in clinical parameters of joint discomfort and allodynia in rats, in addition to showing improvements in radiological and histopathological images, acting on the progress of cartilage deterioration, proving properties related to anti-inflammatory and analgesic processes, being important allies for new therapeutic interventions for the treatment of OA.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




 : 

Was investigated the therapeutic efficacy of the ethyl acetate fraction of Bixa orellana leaves (BoEA) and ellagic acid (ElAc) for the therapeutic treatment of OA induced by monosodium iodoacetate (MIA) in rats and we found that the phytochemical promotes properties related to anti-inflammatory and analgesic processes, being important allies for new therapeutic interventions for the treatment of OA.


Was investigated the therapeutic efficacy of the ethyl acetate fraction of Bixa orellana leaves (BoEA) and ellagic acid (ElAc) for the therapeutic treatment of OA induced by monosodium iodoacetate (MIA) in rats and we found that the phytochemical promotes properties related to anti-inflammatory and analgesic processes, being important allies for new therapeutic interventions for the treatment of OA.ga1

Le texte complet de cet article est disponible en PDF.

Highlights

BoEA and Ellagic acid may be an adjuvant therapy for the treatment of OA.
BoEA and Ellagic acid exhibited an anti-inflammatory effect by increasing IL-10 levels.
BoEA and Ellagic acid also attenuated cartilage degeneration evidenced by the radiological and histological images.
BoEA and Ellagic acid exert beneficial effects on progression at OA.

Le texte complet de cet article est disponible en PDF.

Abbreviations : BoEA, ElAc, HPLC, BoHE, IL1, IL-10, MAPKs, NF-κB, OA, OARSI, TAK1, MMPs, MIA, TLRs, TNF-α

Keywords : Cartilage damage, Joint degeneration, Pain, Antinociception, Analgesia


Plan


© 2023  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 168

Article 115644- décembre 2023 Retour au numéro
Article précédent Article précédent
  • Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice
  • Hesham Shamshoum, Kyle D. Medak, Greg L. McKie, Stewart Jeromson, Margaret K. Hahn, David C. Wright
| Article suivant Article suivant
  • The preventive effects of broccoli bioactives against cancer: Evidence from a validated rat glioma model
  • Nieves Baenas, Angélica Vega-García, Joaquín Manjarrez-Marmolejo, Diego A. Moreno, Iris A. Feria-Romero

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.